by Elena Iemma | Mar 11, 2021 | Events, Webinars
Aimee Mattei, Senior Project Manager on our Bioinformatics team, will be presenting to the AAPS BPABC(biopharmaceutical product attributes and biological consequences) Community on March 18th at 12pm ET. You’ll need to join the group to register, membership is...
by Elena Iemma | Feb 17, 2021 | News
PROVIDENCE, RI, February 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) today announces its participation in the INDIGO consortium – a partnership of public and private research and development organizations from the EU, India, and United States (funded by the...
by Adam | Dec 15, 2020 | News
PROVIDENCE, RI, December 15, 2020 /PRNewswire/ — EpiVax, Inc. reports a record-breaking year for the “ISPRI” immunogenicity screening toolkit. More pharmaceutical and biotechnology companies signed new and continuing licenses for access to the toolkit in 2020...
by Adam | Mar 27, 2020 | News
March 26, 2020 04:42 PM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen...
by Sarah Moniz | Jun 13, 2018 | News
NEW YORK CITY AND PROVIDENCE, RI., June 12, 2018 (BUSINESS WIRE) — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced the closing of a $1.2M Bridge Financing. The investors include NextWaveBio, Morningside Venture Investments, Accelerate...
